Biomerica. has filed a patent for test kits and methods for food sensitivity, focusing on rational-based selection of food preparations with specific discriminatory p-values. The kits are designed for patients with irritable bowel syndrome and include a minimum number of food preparations with established discriminatory p-values. Gender stratification is also considered for enhanced predictive value. GlobalData’s report on Biomerica gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Biomerica Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Biomerica, Molecular diagnosis biomarkers was a key innovation area identified from patents. Biomerica's grant share as of January 2024 was 21%. Grant share is based on the ratio of number of grants to total number of patents.

Test kit for food intolerance in patients with irritable bowel syndrome

Source: United States Patent and Trademark Office (USPTO). Credit: Biomerica Inc

A patent application (Publication Number: US20230417758A1) describes a test kit designed for testing food intolerance in patients diagnosed with or suspected to have irritable bowel syndrome. The kit includes a variety of distinct food preparations coupled to individually addressable solid carriers. These food preparations have specific discriminatory p-values, indicating their effectiveness in identifying food intolerances. The kit allows for testing with a range of food items, including cocoa, tea, oat, cabbage, cow milk, onion, honey, and more, providing a comprehensive approach to identifying potential triggers for food intolerance in patients with irritable bowel syndrome.

Furthermore, the patent application outlines a method for testing food intolerance in patients with irritable bowel syndrome. This method involves contacting a food preparation with a bodily fluid of a patient, allowing IgG from the bodily fluid to bind to components of the food preparation. By measuring IgG bound to these components and comparing the results to gender-stratified reference values, the method can generate a report indicating potential food intolerances. The method also includes steps for normalizing results, identifying subsets of patients with sensitivities to specific food preparations, and determining the numbers of food preparations needed for confirming irritable bowel syndrome. Overall, the patent application presents a comprehensive approach to diagnosing food intolerance in patients with irritable bowel syndrome using a variety of distinct food preparations and solid carriers for testing.

To know more about GlobalData’s detailed insights on Biomerica, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies